^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.

Published date:
05/19/2021
Excerpt:
148 pts randomly assigned to G/C/GV (n = 75; all eotaxine-high)...Median OS was significantly improved in the G/C/GV group with 11.3m...Also, median TTP was significantly improved in the G/C/GV group….G/C/GV treatments significantly extend OS and TTP in advanced PDA than G/C...GV1001 should be considered as one of the options in PDA pts with high serum eotaxin levels.
Secondary therapy:
gemcitabine + capecitabine
DOI:
10.1200/JCO.2021.39.15_suppl.4020
Trial ID: